The company launched last month with initial financing of $35 million and licenses to CRISPR and synthetic biology technology from the Broad and Harvard.
Researchers found that both CBEs and ABEs can cause transcriptome-wide RNA edits, which has implications for the research and therapeutic uses of base editors.
The team reported that engineering a hairpin secondary structure onto the spacer region of sgRNAs can increase specificity by several orders of magnitude.
The researchers created a resource of cancer dependencies and developed a framework to prioritize existing cancer drug targets and suggest new ones.
The firm originally raised $55.5 million in the round in February 2018, and said investors added $30 million in December and another $20 million more recently.
The San Francisco-based startup, which closed a $5 million Series A round in 2017, aims to develop nutritionally enhanced food and feed crops.
The company plans to sell 7.9 million shares of common stock at $16 per share through its initial public offering.
The company has initial financing of $35 million, and has licensed its foundational SHERLOCK and INSPECTR technologies from the Broad and Harvard, respectively.
The agriculture company said it will use the technology it has licensed for new applications in crop editing and for research to bring new foods to market.
The biotech startup, which had been working with Cas12 and Cas13, has now licensed the recently discovered Cas14 protein from UC Berkeley.
A statement from NIH Director Francis Collins follows a call by scientists for the moratorium pending the creation of a framework to guide the use of heritable genome editing.
CRISPR technology has made its way around the world, but in the wake of the He Jiankui controversy, the industry is asking what recourse it has against misuse.
In a different study, investigators found that adenine base editors and cytosine base editors recognize different off-target sites.
The former cofounder of Knome believes that the future of precision medicine lies in our ability to program living things to act as medicines.
The team engineered an enhanced Acidaminococcus sp. Cas12a variant that has the ability to target many previously inaccessible protospacer adjacent motifs.
The company said the financing will further support its strategy of translating its genome editing platforms into potential therapeutics and drug-discovery solutions.
Two new studies identified extensive RNA scaffolds underlying the increased editing efficiency of these nucleases.
Promega said it will combine the CRISPR technology with its own products that are designed for knock-in of genetic reporters into cells or cell lines.
The partners are planning to integrate the technology into Horizon's research tools and services and to develop it for applications in cell therapeutics.
The nuclease, which comes from Bacillus hisashii, has gain-of-function mutations that facilitate robust editing in human cell lines and primary human T cells.
A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.
A new analysis finds some cancers receive more nonprofit dollars than others.
An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.
In Science this week: comparative analysis of sex differences in mammal gene expression, and more.